Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.
Atezolizumab, when added to standard-of-care chemotherapy, significantly improves survival of patients with extensive-stage small-cell lung cancer (SCLC) in the first-line setting, according to results of the IMpower133 trial reported at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC 2018).
Population-based lung cancer screening with multislice CT substantially reduces mortality from the disease among high-risk former and current smokers, with larger risk reductions in women vs men, the NELSON study has shown.
Incorporating reflex testing with a novel next-generation sequencing (NGS) assay with an expanded array of biomarkers was reliable, cost-effective, and efficient in profiling the genomes of patients with advanced non-small-cell lung cancer (NSCLC), thus enabling efficient initiation of targeted therapies for the patients, a new study shows.
While the use of broad-based genomic sequencing helped guide treatment in a small number of cases of advanced non-small-cell lung cancer (NSCLC), it had no apparent impact on survival compared with EGFR and/or ALK mutation testing only, according to a US-based study.
Interstitial lung abnormalities (ILA), a common finding in low-dose chest CT, are associated with a 5.5-fold increase in risk of lung cancer over long-term follow-up, according to a study reported at the European Respiratory Society (ERS) International Congress 2018.
The recent “Best of ASCO” event in Singapore saw a battle of wits among leading oncologists in the region during an insightful debate session on the roles of immunotherapy and biomarkers in non-small–cell lung cancer (NSCLC).
Matching targeted therapy to genetic alterations in the tumour improved response rate and long-term survival in patients with advanced cancer who underwent molecular profiling compared with patients who were unmatched to therapy, highlighting the role of molecular testing in precision medicine, the IMPACT* study shows.
Adding atezolizumab to a combination therapy of bevacizumab plus carboplatin and paclitaxel (CP) significantly improves progression-free survival (PFS) and overall survival (OS) in chemotherapy-naïve patients with metastatic nonsquamous non-small–cell lung cancer (NSCLC), irrespective of PD-L1 expression levels and EGFR or ALK alteration status, according to the IMpower150* trial presented at ASCO 2018.
Segmentectomy and lobectomy confer similar overall survival (OS) and lung cancer-specific survival (LCSS) among patients with primary nonsmall cell lung cancer (NSCLC) of ≤20 mm without lymph node or distant metastasis, a recent study has shown.
The addition of pembrolizumab to a pemetrexed-platinum chemotherapy regimen improved overall survival (OS) and progression-free survival (PFS) in patients with advanced non-squamous non-small-cell lung cancer (NSCLC), findings from the phase III KEYNOTE-189* trial show.
Dr Ong Kian Chung, a respiratory specialist at the KC Ong Chest & Medical Clinic, Mount Elizabeth Medical Centre, Singapore spoke on the evils of tobacco use and how clinicians can help in smoking cessation.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.